参考文献/References:
[1]. Aguilar D,Deswal A,Ramasubbu K,et al.Comparison of patients with heart failure and preserved left ventricular ejection fraction among those with versus without diabetes mellitus[J].Am J Cardiol,2010,105(3):373-377.
[2].Lehrke M,Marx N.Diabetes mellitus and heart failure[J].Am J Cardiol,2017,120(1S):S37-S47.
[3].Zinman B,Wanner C,Lachin JM,et al.Empagliflozin,cardiovascular outcomes,and mortality in type 2 diabetes[J].N Engl J Med,2015,373(22):2117-2128.
[4].Ong CR,Molyneaux LM,Constsntino MI,et al.Long-term efficacy of metformin therapy in nonobese individuals with type 2 diabetes[J].Diabetes Care,2006,29(11):2361-2364.
[5].Scirica BM,Bhatt DL,Braunwald E,et al.Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus[J].N Engl J Med,2013,369(14):1317-1326.
[6].Marso SP,Daniels GH,Brown-Frandsen K,et al.Liraglutide and cardiovascular outcomes in type 2 diabetes[J].N Engl J Med,2016,375(4):311-322.
[7].Marso SP,Bain SC,Consoli A,et al.Semaglutide and cardiovascular outcomes in patients with type 2 diabetes[J].N Engl J Med,2016,375(19):1834-1844.
[8].Gerich JE.Role of the kidney in normal glucose homeostasis and in the hyperglycaemia of diabetes mellitus:therapeutic implications[J].Diabet Med,2010,27(2):136-142.
[9].Vallon V,Gerasimova M,Rose MA,et al.SGLT2 inhibitor empagliflozin reduces renal growth and albuminuria in proportion to hyperglycemia and prevents glomerular hyperfiltration in diabetic Akita mice[J].Am J Physiol Renal Physiol,2014,306(2):F194-F204.
[10]. Stanley WC ,Recchia FA,Lopaschuk GD.Myocardial substrate metabolism in the normal and failing heart[J].Physiol Rev,2005,85(3):1093-1129.
[11]. Joubert M,Jagu B,Montaigne D,et al.The sodium-glucose cotransporter 2 inhibitor dapagliflozin prevents cardiomyopathy in a diabetic lipodystrophic mouse model[J].Diabetes,2017,66(4):1030-1040.
[12]. Ferrannini E,Baldi S,Frascerra S,et al.Shift to fatty substrate utilization in response to sodium-glucose cotransporter 2 inhibition in subjects without diabetes and patients with type 2 diabetes[J].Diabetes,2016,65(5):1190-1195.
[13]. H?ring HU ,Merker L,Seewaldt-Becker E,et al.Empagliflozin as add-on to metformin in patients with type 2 diabetes:a 24-Week,randomized,double-blind,placebo-controlled trial[J].Diabetes Care,2014,37(6):1650-1659.
[14]. Weidmann P,Ferrari P.Central role of sodium in hypertension in diabetic subjects[J].Diabetes Care,1991,14(3):220-232.
[15]. 高斯德,李卫萍,李虹伟,等.钠-葡萄糖协同转运蛋白抑制剂与心力衰竭的研究进展[J].心血管病学进展,2018,39(5):703-708.
[16]. Lytvyn Y,Bjornstad P,Udell JA,et al.Sodium glucose contransporter-2 inhibition in heart failure :potential mechanisms,clinical applications,and summary of clinical trials[J].Circulation,2017,136(17):1643-1658.
[17]. Inzucchi SE,Zinman B,Fitchett D,et al.How does empagliflozin reduce cardiovascular mortality? Insights from a mediation analysis of the EMPA-REG OUTCOME trial[J].Diabetes Care,2018,41(2):356-363.
[18]. Baartscheer A,Schumacher CA ,Wüst RC,et al.Empagliflozin decreases myocardial cytoplasmic Na+ through inhibition of the cardiac Na +/H+ exchanger in rats and rabbits[J].Diabetologia,2017,60(3):568-573.
[19]. Liu T,Takimoto E,Dimaano VL,et al.Inhibiting mitochondrial Na +/Ca2+ exchange prevents sudden death in a Guinea pig model of heart failure[J].Circ Res,2014,115(1):44-54.
[20]. Bertero E,Prates Roma L,Ameri P,et al.Cardiac effects of SGLT2 inhibitors :the sodium hypothesis[J].Cardiovasc Res,2018,114(1):12-18.
[21]. Feldman-Billard S.Comment on Kaul. Mitigating cardiovascular risk in type 2 diabetes with antidiabetes drugs:a review of principal cardiovascular outcome results of EMPA-REG OUTCOME,LEADER,and SUSTAIN-6 trials[J]. Diabetes Care,2017;40(12):e174.
[22]. 包丽雯,李勇.SGLT2抑制剂恩格列净心血管保护作用及研究－EMPA-HEART Cardiolink 6研究简评[J].中国糖尿病杂志,2019,27(7):557-560.
[23]. Filippatos TD,Tsimihodimos V ,Elisaf MS.Mechanisms of blood pressure reduction with sodium-glucose co-transporter 2(SGLT2) inhibitors[J].Expert Opin Pharmacother,2016,17(12):1581-1583.
[24]. Maliha G,Townsend RR.SGLT2 inhibitors :their potential reduction in blood pressure[J].J Am Soc Hypertens,2015,9(1):48-53.
[25]. Prasad M,Matteson EL,Herrmann J,et al.Uric acid is associated with inflammation ,coronary microvascular dysfunction,and adverse outcomes in postmenopausal women[J].Hypertension,2017,69(2):236-242.
[26]. Tanaka T,Milaneschi Y,Zhang Y,et al.A double blind placebo controlled randomized trial of the effect of acute uric acid changes on inflammatory markers in humans :A pilot study[J].PLoS One,2017,12(8):e0181100.
[27]. . Cheeseman C.Solute carrier family 2,member 9 and uric acid homeostasis[J].Curr Opin Nephrol Hypertens,2009,18(5):428-432.
[28]. Ridderstr?le M ,Andersen KR,Zeller C,et al.Comparison of empagliflozin and glimepiride as add-on to metformin in patients with type 2 diabetes:a 104-week randomized,active-controlled,double-blind,phase 3 trial[J].Lancet Diabetes Endocrinol,2014,2(9):691-700.
[29]. Vallon V,Thomson SC.Targeting renal glucose reabsorption to treat hyperglycaemia :the pleiotropic effects of SGLT2 inhibition[J].Diabetologia,2017,60(2):215-225.
[30]. Matsutani D,Sakamoto M,Kayama Y,et al.Effect of canagliflozin on left ventricular diastolic function in patients with type 2 diabetes[J].Cardiovasc Diabetol,2018,17(1):73.
[31]. 杨杰孚.心力衰竭药物治疗进展[J].心电与循环,2019,38(5):367-371.